The imidazoline I2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes

European Journal of Pharmacology

Volumn 552, Issue 1-3, 2006, Pages 20-30

  Bour, Sandy ^a   Iglesias Osma, María Carmen ^c   Marti, Luc ^b   Duro, Piedad ^c   Garcia Barrado, María José ^c   Pastor, Maria Francisca ^c   Prévot, Danielle ^a   Visentin, Virgile ^a   Valet, Philippe ^a   Moratinos, Julio ^c   Carpéné, Christian ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Adipose tissue; Imidazoline site ligand; Insulin; MAO (Monoamine oxidase); SSAO (Semicarbazide sensitive amine oxidase)

Indexed keywords

2 (2 BENZOFURANYL) 2 IMIDAZOLINE; 2 (2 IMIDAZOLIN 2 YL)QUINOLINE; 2 BENZOFURANYL 2 IMIDAZOLINE; ALPHA 2 ADRENERGIC RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBON 14; GLUCOSE; HYDROGEN PEROXIDE; IMIDAZOLINE DERIVATIVE; IMIDAZOLINE I2 RECEPTOR; INSULIN; LIGAND; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; SEMICARBAZIDE; TYRAMINE; UNCLASSIFIED DRUG; 2-(2-BENZOFURANYL)-2-IMIDAZOLINE; AMINE OXIDASE (COPPER CONTAINING); BENZOFURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; MONOAMINE OXIDASE INHIBITOR;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; INHIBITION KINETICS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOLYSIS; LIVER; LONG TERM CARE; MALE; MEASUREMENT; MODULATION; MOUSE; NONHUMAN; OBESITY; OBSERVATION; OXIDATION; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN FUNCTION; RABBIT; RAT; RECEPTOR UPREGULATION; THROMBOCYTE; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ANIMAL; BINDING SITE; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; WISTAR RAT; ZUCKER RAT;

ADIPOCYTES; ADIPOSE TISSUE; AMINE OXIDASE (COPPER-CONTAINING); ANIMALS; BENZOFURANS; BINDING SITES; BLOOD PLATELETS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; HUMANS; HYDROGEN PEROXIDE; IMIDAZOLES; IMIDAZOLINES; LIPOLYSIS; LIVER; MALE; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; RABBITS; RATS; RATS, WISTAR; RATS, ZUCKER;

EID: 33751051518     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.09.021     Document Type: Article

References (47)

1. Anderson N.J., Lupo P.A., Nutt D.J., Hudson A.L., and Robinson E.S. Characterisation of imidazoline I2 binding sites in pig brain. Eur. J. Pharmacol. 519 (2005) 68-74
2. Atgié C., Tavernier G., D'Allaire F., Bengtsson T., Marti L., Carpéné C., Lafontan M., Bukowiecki L.J., and Langin D. Beta 3-adrenoceptor in guinea pig brown and white adipocytes: low expression and lack of function. Am. J. Physiol. 271 (1996) R1729-R1738
3. Carpéné C., Galitzky J., Larrouy D., Langin D., and Lafontan M. Non-adrenergic sites for imidazolines are not directly involved in the alpha 2-adrenergic antilipolytic effect of UK 14304 in rat adipocytes. Biochem. Pharmacol. 40 (1990) 437-445
4. Carpéné C., Collon P., Remaury A., Cordi A., Hudson A., Nutt D., and Lafontan M. Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites. J. Pharmacol. Exp. Ther. 272 (1995) 681-688
5. Carpéné C., Marti L., Hudson A., and Lafontan M. Nonadrenergic imidazoline binding sites and amine oxidase activities in fat cells. Ann. N.Y. Acad. Sci. 763 (1995) 380-397
6. Carpéné C., Bour S., Visentin V., Pellati F., Benvenuti S., Iglesias-Osma M.C., Garcia-Barrado M.J., and Valet P. Amine oxidase substrates for impaired glucose tolerance correction. J. Physiol. Biochem. 61 (2005) 405-419
7. Chan S.L., Brown C.A., and Morgan N.G. Stimulation of insulin secretion by the imidazoline alpha 2-adrenoceptor antagonist efaroxan is mediated by a novel, stereoselective, binding site. Eur. J. Pharmacol. 230 (1993) 375-378
8. Chan S.L., Brown C.A., Scarpello K.E., and Morgan N.G. Pancreatic beta-cells express an imidazoline binding site that is distinct from I1 and I2 sites. Ann. N.Y. Acad. Sci. 763 (1995) 153-156
9. Choi S.H., Choi D.H., Lee J.J., Park M.S., and Chun B.G. Imidazoline drugs stabilize lysosomes and inhibit oxidative cytotoxicity in astrocytes. Free Radic. Biol. Med. 32 (2002) 394-405
10. Claus T.H., Lowe D.B., Liang Y., Salhanick A.I., Lubeski C.K., Yang L., Lemoine L., Zhu J., and Clairmont K.B. Specific inhibition of hormone-sensitive lipase improves lipid profile while reducing plasma glucose. J. Pharmacol. Exp. Ther. 315 (2005) 1396-1402
11. Efendic S., Efanov A.M., Berggren P.O., and Zaitsev S.V. Two generations of insulinotropic imidazoline compounds. Diabetes 51 Suppl 3 (2002) S448-S454
12. Eglen R.M., Hudson A.L., Kendall D.A., Nutt D.J., Morgan N.G., Wilson V.G., and Dillon M.P. 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol. Sci. 19 (1998) 381-390
13. Enrique-Tarancon G., Castan I., Morin N., Marti L., Abella A., Camps M., Casamitjana R., Palacin M., Testar X., Degerman E., Carpéné C., and Zorzano A. Substrates of semicarbazide-sensitive amine oxidase co-operate with vanadate to stimulate tyrosine phosphorylation of insulin-receptor-substrate proteins, phosphoinositide 3-kinase activity and GLUT4 translocation in adipose cells. Biochem. J. 350 (2000) 171-180
14. Finn D.P., Lalies M.D., Harbuz M.S., Jessop D.S., Hudson A.L., and Nutt D.J. Imidazoline(2) (I(2)) binding site- and alpha(2)-adrenoceptor-mediated modulation of central noradrenergic and HPA axis function in control rats and chronically stressed rats with adjuvant-induced arthritis. Neuropharmacology 42 (2002) 958-965
15. Holt A. Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs?. J. Psychiatry Neurosci. 28 (2003) 409-414
16. Holt A., Wieland B., and Baker G.B. Allosteric modulation of semicarbazide amine oxidase activities in vitro by imidazoline receptor ligands. Br. J. Pharmacol. 143 (2004) 495-507
17. Hosseini A.R., King P.R., Louis W.J., and Gundlach A.L. [3H]2-(2-Benzofuranyl)-2-imidazoline, a highly selective radioligand for I2-imidazoline receptor binding sites. Studies in rabbit kidney membranes. Naunyn Schmiedeberg's Arch. Pharmacol. 355 (1997) 131-138
18. Hudson A.L., Gough R., Tyacke R., Lione L., Lalies M., Lewis J., Husbands S., Knight P., Murray F., Hutson P., and Nutt D.J. Novel selective compounds for the investigation of imidazoline receptors. Ann. N.Y. Acad. Sci. 881 (1999) 81-91
19. Iglesias-Osma M.C., Bour S., Garcia-Barrado M.J., Visentin V., Pastor M.F., Testar X., Marti L., Enrique-Tarancon G., Valet P., Moratinos J., and Carpéné C. Methylamine but not mafenide mimics insulin-like activity of the semicarbazide-sensitive amine oxidase-substrate benzylamine on glucose tolerance and on human adipocyte metabolism. Pharmacol. Res. 52 (2005) 475-484
20. Lafontan M., Langin D., Portillo M., and Paris H. Imidazoline binding sites in fat cells. Localization and pharmacologic differentiation from alpha 2-adrenergic receptors. Am. J. Hypertens. 5 (1992) 72S-79S
21. Langin D., Paris H., and Lafontan M. Binding of [3H]idazoxan and of its methoxy derivative [3H] RX821002 in human fat cells: [3H]idazoxan but not [3H] RX821002 labels additional non-alpha 2-adrenergic binding sites. Mol. Pharmacol. 37 (1990) 876-885
22. Lyles G.A. Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: biochemical, pharmacological and toxicological aspects. Int. J. Biochem. Cell Biol. 28 (1996) 259-274
23. MacInnes N., and Duty S. Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway. Br. J. Pharmacol. 143 (2004) 952-959
24. MacInnes N., and Handley S.L. Characterization of the discriminable stimulus produced by 2-BFI: effects of imidazoline I(2)-site ligands, MAOIs, beta-carbolines, agmatine and ibogaine. Br. J. Pharmacol. 135 (2002) 1227-1234
25. Marti L., Morin N., Enrique-Tarancon G., Prevot D., Lafontan M., Testar X., Zorzano A., and Carpene C. Tyramine and vanadate synergistically stimulate glucose transport in rat adipocytes by amine oxidase-dependent generation of hydrogen peroxide. J. Pharmacol. Exp. Ther. 285 (1998) 342-349
26. Marti L., Abella A., Carpéné C., Palacin M., Testar X., and Zorzano A. Combined treatment with benzylamine and low dosages of vanadate enhances glucose tolerance and reduces hyperglycemia in streptozotocin-induced diabetic rats. Diabetes 50 (2001) 2061-2068
27. Mayer G., and Taberner P.V. Effects of the imidazoline ligands efaroxan and KU14R on blood glucose homeostasis in the mouse. Eur. J. Pharmacol. 454 (2002) 95-102
28. Morgan N.G. Imidazoline receptors: new targets for antihyperglycaemic drugs. Expert Opin. Investig. Drugs 8 (1999) 575-584
29. Morgan N.G., and Chan S.L. Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues?. Curr. Pharm. Dev. 7 (2001) 1413-1431
30. Morin N., Lizcano J.M., Fontana E., Marti L., Smih F., Rouet P., Prevot D., Zorzano A., Unzeta M., and Carpéné C. Semicarbazide-sensitive amine oxidase substrates stimulate glucose transport and inhibit lipolysis in human adipocytes. J. Pharmacol. Exp. Ther. 297 (2001) 563-572
31. Morin N., Visentin V., Calise D., Marti L., Zorzano A., Testar X., Valet P., Fischer Y., and Carpéné C. Tyramine stimulates glucose uptake in insulin-sensitive tissues in vitro and in vivo via its oxidation by amine oxidases. J. Pharmacol. Exp. Ther. 303 (2002) 1238-1247
32. Parini A., Moudanos C.G., Pizzinat N., and Lanier S.M. The elusive family of imidazoline binding sites. Trends Pharmacol. Sci. 17 (1996) 13-16
33. Pele-Tounian A., Chan S.L., Rondu F., Le Bihan G., Giroix M.H., Lamouri A., Touboul E., Pfeiffer B., Manechez D., Renard P., Guardiola-Lemaitre B., Godfroid J.J., Penicaud L., Morgan N.G., and Ktorza A. Effect of the new imidazoline derivative S-22068 (PMS 847) on insulin secretion in vitro and glucose turnover in vivo in rats. Eur. J. Pharmacol. 377 (1999) 81-87
34. Pizzinat N., Marti L., Remaury A., Leger F., Langin D., Lafontan M., Carpéné C., and Parini A. High expression of monoamine oxidases in human white adipose tissue: evidence for their involvement in noradrenaline clearance. Biochem. Pharmacol. 58 (1999) 1735-1742
35. Raddatz R., and Lanier S.M. Relationship between imidazoline/guanidinium receptive sites and monoamine oxidase A and B. Neurochem. Int. 30 (1997) 109-117
36. Raddatz R., Savic S.L., Bakthavachalam V., Lesnick J., Jasper J.R., McGrath C.R., Parini A., and Lanier S.M. Imidazoline-binding domains on monoamine oxidase B and subpopulations of enzyme. J. Pharmacol. Exp. Ther. 292 (2000) 1135-1145
37. Saulnier-Blache J.S., Carpéné C., Langin D., and Lafontan M. Imidazolinic radioligands for the identification of hamster adipocyte alpha 2-adrenoceptors. Eur. J. Pharmacol. 171 (1989) 145-157
38. Schulz A., and Hasselblatt A. An insulin-releasing property of imidazoline derivatives is not limited to compounds that block alpha-adrenoceptors. Naunyn Schmiedeberg's Arch. Pharmacol. 340 (1989) 321-327
39. Tesson F., Limon-Boulez I., Urban P., Puype M., Vandekerckhove J., Coupry I., Pompon D., and Parini A. Localization of I2-imidazoline binding sites on monoamine oxidases. J. Biol. Chem. 270 (1995) 9856-9861
40. Velliquette R.A., and Ernsberger P. The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. J. Pharmacol. Exp. Ther. 306 (2003) 646-657
41. Velliquette R.A., Kossover R., Previs S.F., and Ernsberger P. Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn Schmiedeberg's Arch. Pharmacol. 372 (2006) 300-312
42. Visentin V., Prévot D., Marti L., and Carpéné C. Inhibition of rat fat cell lipolysis by monoamine oxidase and semicarbazide-sensitive amine oxidase substrates. Eur. J. Pharmacol. 466 (2003) 235-243
43. Visentin V., Bour S., Boucher J., Prévot D., Valet P., Ordener C., Parini A., and Carpéné C. Glucose handling in streptozotocin-induced diabetic rats is improved by tyramine but not by the amine oxidase inhibitor semicarbazide. Eur. J. Pharmacol. 522 (2005) 139-146
44. Wang X., Rondu F., Lamouri A., Dokhan R., Marc S., Touboul E., Pfeiffer B., Manechez D., Renard P., Guardiola-Lemaitre B., Godfroid J.J., Ktorza A., and Penicaud L. Effect of S-21663 (PMS 812), an imidazoline derivative, on glucose tolerance and insulin secretion in a rat model of type II diabetes. J. Pharmacol. Exp. Ther. 278 (1996) 82-89
45. Wiest S.A., and Steinberg M.I. 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine. Naunyn Schmiedeberg's Arch. Pharmacol. 360 (1999) 209-216
46. Yu P.H., Wang M., Fan H., Deng Y., and Gubisne-Haberle D. Involvement of SSAO-mediated deamination in adipose glucose transport and weight gain in obese diabetic KKAy mice. Am. J. Physiol., Endocrinol Metabol. Gastrointest. Physiol. 286 (2004) E634-E641
47. Zhu H., and Piletz J.E. Association between I(2) binding sites and monoamine oxidase-B activity in platelets. Ann. N.Y. Acad. Sci. 1009 (2003) 347-352